Urology Search
Urology Urology
erectile%20dysfunction
ERECTILE DYSFUNCTION

Erectile dysfunction is the inability to attain and maintain an erection enough to have satisfactory sexual performance for ≥3 months.

It is when the patient complains of partial erection that could not attain vaginal penetration.

Complete loss of penile rigidity is uncommon.

Initial penile erections can penetrate but early detumescence occurs without ejaculation.

Definition

  • Inability to attain & maintain an erection enough to have satisfactory sexual performance for at least 3 months

Etiology

  • Increasing evidence have shown that erectile dysfunction can be an early manifestation of coronary artery & peripheral vascular disease

Signs and Symptoms

  • Complete loss of penile rigidity is uncommon
  • A patient may complain of partial erection that could not attain vaginal penetration
  • Initial penile erections can penetrate but early detumescence occurs without ejaculation
  • Nocturnal penile tumescence
  • Inability to maintain erection during private masturbation and/or erections related to erotic materials or other partners

Risk Factors

  • Erectile dysfunction has common risk factors as w/ cardiovascular diseases
  • Studies have shown that erectile dysfunction has been associated w/ lower urinary tract symptoms, benign prostatic hyperplasia, & sexual dysfunction regardless of age & other comorbidities & various lifestyle factors
Comorbidities & other risk factors that may contribute to erectile dysfunction:
Arteriogenic
  • Diabetes mellitus
  • Hypertension
  • Cardiovascular disease
  • Hyperlipidemia & the metabolic syndrome
  • Heavy smoking
  • Peripheral vascular disorders
  • Recreational drug abuse
Neurogenic
  • Trauma
  • Spinal cord injury
Endocrine
  • Diabetes mellitus
  • Hypogonadism/testosterone deficiency
  • Hyperprolactinemia
  • Hyper- & hypothyroidism
  • Obesity
Psychiatric & Psychogenic
  • Depression
  • Anxiety disorders
  • Relationship issues
  • Stress
  • Performance anxiety
  • Loss of attraction
Drugs
  • Antiandrogens (eg Finasteride) 
  • Antihypertensives (beta-blockers, Spironolactone, Methyldopa, thiazide diuretics)
  • Narcotics
  • Cimetidine
  • Antidepressants
  • Tranquillizers
  • Others
Penile Disorders
  • Peyronie’s disease
  • Severe phimosis
Others
  • Alcohol abuse
  • Obstructive sleep apnea 
  • Pelvic and prostatic radiation therapy
  • Pelvic and prostate surgery [eg transuretheral resection of the prostate (TURP), radical prostatectomy 
  • Sedentary lifestyle
Editor's Recommendations
Most Read Articles
Strong belief in medication necessity tied to better adherence in RA patients
5 days ago
A strong belief in the necessity of medication is associated with better adherence to oral disease-modifying antirheumatic drugs (DMARDs) or prednisone, while higher self-efficacy correlates with poor adherence, in a diverse cohort of patients with rheumatoid arthritis (RA), suggests a study.
Low-dose haloperidol ineffective against delirium following thoracic surgery
4 days ago
Low-dose administrations of haloperidol after thoracic surgery does not appear to prevent postoperative delirium, according to a new study.
PCI vs CABG shows similar rates of mortality but higher target-vessel revascularizations at 10 years
2 days ago
Percutaneous coronary intervention (PCI) displays comparable rates of mortality and serious composite outcomes but a higher rate of target-vessel revascularization at 10 years relative to coronary artery bypass grafting (CABG) in patients with significant left main coronary artery (LMCA) disease, reports a study. On the other hand, CABG delivers lower mortality and serious composite outcome rates compared with PCI with drug-eluting stents after 5 years.
Apixaban trumps standard treatment in preventing cancer-associated VTE recurrence
Pearl Toh, 4 days ago
Apixaban slashes the risk of recurrent venous thromboembolism (VTE) by 90 percent in cancer patients compared with the low-molecular-weight heparin (LMWH) dalteparin, with no increase in major bleeding risk, according to the ADAM VTE study presented at ASH 2018.